Souhaitez-vous accéder aux communiqués récents ?

LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

The biotechnology space is delivering market-moving developments, as companies across oncology, neuroscience, gene therapy, medical devices, and more

~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~ ~ Company intends to submit the BLA in third quarter...

New real-world survey data reveal the daily impact of Huntington’s disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing1 and up to 83% of...

New York, May 06, 2026 (GLOBE NEWSWIRE) -- One of the most influential figures in modern genetic research, Nancy S. Wexler, PhD, led the pioneering fieldwork that helped make possible the discovery...

~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~ ~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential...

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

LEXINGTON, Mass. and AMSTERDAM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease...

LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...